INDP Stock Price | Indaptus Therapeutics Inc P/E, Revenue, EPS, & Forecasts

Indaptus Therapeutics Inc • INDP

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Indaptus Therapeutics Inc

Ticker

INDP

Trading on

NASDAQ

ISIN

US45339J1051

Industry

Biotechnology

Sector

Healthcare

CEO

Jeffrey A. Meckler J.D.

Headquarters

Three Columbus Circle, New York, NY, United States, 10019

Employees

Website

https://indaptusrx.com

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Metrics

BasicAdvanced

Market cap

$3.8M

P/E ratio

EPS

-$29.03

Dividend Yield

0.00%

Beta

1.03

Forward P/E ratio

EBIDTA

$-15.8M

Ex dividend date

Price & volume

Market cap

$3.8M

Average daily volume

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

Price to book

0.82

Earnings

EPS

-$29.03

EPS estimate (current quarter)

-$4.17

EPS estimate (next quarter)

-$4.32

EBITDA

$-15.8M

Revenues (TTM)

$0M

Revenues per share (TTM)

$0.00

Technicals

Beta

1.03

52-week High

$29.68

52-week Low

$1.65

50-day moving average

$3.05

200-day moving average

$9.79

Short ratio

0.18

Short %

0.69%

Management effectiveness

ROE (TTM)

-317.98%

ROA (TTM)

-131.38%

Profit margin

0.00%

Gross profit margin

$0M

Operating margin

0.00%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

0.00%

Share stats

Outstanding Shares

1.8M

Float

1.5M

Insiders %

12.40%

Institutions %

4.11%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 1 analysts.

Average price target

$10.00

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.37

-$0.47

21.28%

Q4 • 24Beat

-$9.00

-$0.18

-4,900.00%

Q1 • 25Missed

-$9.09

-$0.19

-4,684.21%

Q2 • 25Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0M

$-5.2M

-∞%

Q2 • 25

$0M

$-3M

-∞%

Q3 • 25

NaN%

-43.10%

NaN%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$6.8M

$8.5M

124.47%

Q2 • 25

$6.8M

$2.2M

32.67%

Q3 • 25

0.01%

-73.75%

-73.76%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-4M

$6.3M

$-4M

Q2 • 25

$-3.1M

$2.7M

$-3.1M

Q3 • 25

-23.98%

-56.68%

-23.98%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Indaptus Therapeutics Inc share?

Indaptus Therapeutics Inc shares are currently traded for undefined per share.

How many shares does Indaptus Therapeutics Inc have?

Indaptus Therapeutics Inc currently has 1.8M shares.

Does Indaptus Therapeutics Inc pay dividends?

No, Indaptus Therapeutics Inc doesn't pay dividends.

What is Indaptus Therapeutics Inc 52 week high?

Indaptus Therapeutics Inc 52 week high is $29.68.

What is Indaptus Therapeutics Inc 52 week low?

Indaptus Therapeutics Inc 52 week low is $1.65.

What is the 200-day moving average of Indaptus Therapeutics Inc?

Indaptus Therapeutics Inc 200-day moving average is $9.79.

Who is Indaptus Therapeutics Inc CEO?

The CEO of Indaptus Therapeutics Inc is Jeffrey A. Meckler J.D..

How many employees Indaptus Therapeutics Inc has?

Indaptus Therapeutics Inc has 7 employees.

What is the market cap of Indaptus Therapeutics Inc?

The market cap of Indaptus Therapeutics Inc is $3.8M.

What is the P/E of Indaptus Therapeutics Inc?

The current P/E of Indaptus Therapeutics Inc is null.

What is the EPS of Indaptus Therapeutics Inc?

The EPS of Indaptus Therapeutics Inc is -$29.03.

What is the PEG Ratio of Indaptus Therapeutics Inc?

The PEG Ratio of Indaptus Therapeutics Inc is null.

What do analysts say about Indaptus Therapeutics Inc?

According to the analysts Indaptus Therapeutics Inc is considered a buy.